Medicine
Daxxify 100 units/1.2 mL powder for injection
Daxxify 100 units/1.2 mL powder for injection is a prescription medicine containing Botulinum toxin type a for intramuscular use, marketed by Revance Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Unopened DAXXIFY vials should be stored at room temperature 20°C to 25°C (68°F…
Key facts
- Active ingredient (INN)
- Botulinum toxin type a
- Brand
- Daxxify
- Strength
- 100 units/1.2 mL
- Dosage form
- Powder for injection
- Route
- Intramuscular
- Packs
- 1 vial
- Marketing authorisation holder
- Revance Therapeutics
- Manufacturer
- Revance Therapeutics
- Origin register
- US FDA, United States
- Storage
- Unopened DAXXIFY vials should be stored at room temperature 20°C to 25°C (68°F to 77°F) or refrigerated at 2°C to 8° C (36°F to 46°F) in the original carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 September 2022
- Identifiers
- DailyMed set ID 3aaa6e14-a3f7-4fb2-b9f9-d3a9c3ae1f74NDC 72960-112Application BLA761127
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 1.2 mL in 1 vial, single-use | 72960-112-01 | Revance Therapeutics | 20 September 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Botulinum toxin type a
Clinical summary
Botulinum toxin type a is an acetylcholine release inhibitor indicated for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/ or procerus muscle activity in adult patients. MedsAcross supplies Botulinum toxin type a for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Botulinum toxin type aFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- DAXXIFY prescribing information (Revance Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Daxxify 100 units/1.2 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.